Weekly Analysts’ Ratings Changes for Amgen (AMGN)

Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:

• 9/28/2026 – Amgen had its price target raised by Scotiabank from $450.00 to $500.00. They now have an “outperform” rating on the stock.
• 9/23/2026 – Amgen had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $410.00 price target on the stock.
• 9/23/2026 – Amgen had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 9/17/2026 – Amgen had its “buy” rating reaffirmed by UBS Group AG. They now have a $430.00 price target on the stock.
• 9/10/2026 – Amgen was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $425.00 price target on the stock, down from $445.00.
• 9/8/2026 – Amgen was downgraded by BMO Capital Markets from “outperform” to “market perform”. They now have a $450.00 price target on the stock.
• 9/8/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $400.00 price target on the stock.
• 9/4/2026 – Amgen had its price target raised by Wells Fargo & Company from $400.00 to $435.00. They now have an “equal weight” rating on the stock.
• 8/20/2026 – Amgen had its price target raised by Piper Sandler from $427.00 to $457.00. They now have an “overweight” rating on the stock.
• 8/19/2026 – Amgen had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $362.00 price target on the stock.
• 8/19/2026 – Amgen had its price target raised by Argus from $375.00 to $460.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Amgen had its price target raised by Cantor Fitzgerald from $350.00 to $400.00. They now have a “neutral” rating on the stock.
• 8/18/2026 – Amgen had its price target raised by Mizuho from $303.00 to $352.00. They now have a “neutral” rating on the stock.
• 8/14/2026 – Amgen had its price target raised by Barclays PLC from $360.00 to $380.00. They now have an “equal weight” rating on the stock.
• 8/10/2026 – Amgen had its price target raised by Guggenheim from $343.00 to $388.00. They now have a “neutral” rating on the stock.
• 8/8/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Amgen had its price target raised by Citigroup Inc. from $345.00 to $405.00. They now have a “neutral” rating on the stock.
• 8/6/2026 – Amgen was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/6/2026 – Amgen had its price target raised by Sanford C. Bernstein from $335.00 to $345.00. They now have a “market perform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by UBS Group AG from $420.00 to $440.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by TD Cowen from $420.00 to $452.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have a “sector outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Truist Financial Corporation from $340.00 to $362.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Oppenheimer Holdings, Inc. from $400.00 to $450.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Morgan Stanley from $333.00 to $351.00. They now have an “equal weight” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Royal Bank Of Canada from $370.00 to $400.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Robert W. Baird from $215.00 to $230.00. They now have an “underperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Bank of America Corporation from $312.00 to $317.00. They now have an “underperform” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Canaccord Genuity Group Inc. from $366.00 to $384.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by Wells Fargo & Company from $390.00 to $400.00. They now have an “equal weight” rating on the stock.
• 8/5/2026 – Amgen had its price target raised by BMO Capital Markets from $400.00 to $450.00. They now have an “outperform” rating on the stock.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.5%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by insiders.

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.